Cargando…

Altered Bioavailability and Pharmacokinetics in Crohn’s Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs

BACKGROND AND OBJECTIVE: Crohn’s disease (CD) is a chronic inflammatory bowel disease that affects a wide age range. Hence, CD patients receive a variety of drugs over their life beyond those used for CD itself. The changes to the integrity of the intestine and its drug metabolising enzymes and tran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alrubia, Sarah, Mao, Jialin, Chen, Yuan, Barber, Jill, Rostami-Hodjegan, Amin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553790/ https://www.ncbi.nlm.nih.gov/pubmed/36056298 http://dx.doi.org/10.1007/s40262-022-01169-4

Ejemplares similares

Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence
por: Rostami‐Hodjegan, Amin
Publicado: (2017)

Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?
por: Frechen, Sebastian, et al.
Publicado: (2022)

Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn’s Disease Patients through PBPK Modeling
por: Han, Chunyan, et al.
Publicado: (2023)

Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine
por: Darwich, A S, et al.
Publicado: (2013)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz
por: Chetty, Manoranjenni, et al.
Publicado: (2018)

Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory
por: Calvier, Elisa A. M., et al.
Publicado: (2018)

Using Prior Knowledge on Systems Through PBPK to Gain Further Insight into Routine Clinical Data on Trough Concentrations: The Case of Tacrolimus in Chronic Kidney Disease
por: El-Khateeb, Eman, et al.
Publicado: (2023)

Animal versus human oral drug bioavailability: Do they correlate?
por: Musther, Helen, et al.
Publicado: (2014)

Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling
por: Mao, Jialin, et al.
Publicado: (2018)

A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction
por: Ke, A B, et al.
Publicado: (2012)

Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability
por: Chetty, Manoranjenni, et al.
Publicado: (2014)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data
por: Olivares-Morales, Andrés, et al.
Publicado: (2013)

Mass spectrometry‐based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin
por: Al‐Majdoub, Zubida M., et al.
Publicado: (2020)

Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model
por: Chetty, Manoranjenni, et al.
Publicado: (2015)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats
por: Cuello, W. S., et al.
Publicado: (2012)

Current Approaches and Techniques in Physiologically Based Pharmacokinetic (PBPK) Modelling of Nanomaterials
por: Utembe, Wells, et al.
Publicado: (2020)

Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development
por: Shaik, Abdul Naveed, et al.
Publicado: (2019)

Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment
por: El-Khateeb, Eman, et al.
Publicado: (2021)

Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling
por: Doki, Kosuke, et al.
Publicado: (2019)

Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients
por: Kovar, Lukas, et al.
Publicado: (2020)

In Vitro Dissolution and In Vivo Bioavailability of Six Brands of Ciprofloxacin Tablets Administered in Rabbits and Their Pharmacokinetic Modeling
por: Fahmy, Sahar, et al.
Publicado: (2014)

Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator‐Formulated Itraconazole Capsules and Solution in Healthy Dogs
por: Hasbach, A.E., et al.
Publicado: (2017)

Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making
por: Rowland, M, et al.
Publicado: (2015)

Proof of Concept in Assignment of Within-Subject Variability During Virtual Bioequivalence Studies: Propagation of Intra-Subject Variation in Gastrointestinal Physiology Using Physiologically Based Pharmacokinetic Modeling
por: Bego, Margareta, et al.
Publicado: (2022)

Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models
por: Liu, Dan, et al.
Publicado: (2020)

Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug–drug interaction prediction
por: Gill, Jaidip, et al.
Publicado: (2022)

Development of a Human Physiologically Based Pharmacokinetic (PBPK) Toolkit for Environmental Pollutants
por: Ruiz, Patricia, et al.
Publicado: (2011)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Interstrain Variability in Trichloroethylene Metabolism in the Mouse
por: Chiu, Weihsueh A., et al.
Publicado: (2014)

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates
por: Kovar, Lukas, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Brain Levels of Drug in Rat
por: Sánchez-Dengra, Bárbara, et al.
Publicado: (2021)

Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically‐Based Pharmacokinetic Modeling and Dose Adjustment
por: Tan, Shawn Pei Feng, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic (PBPK) Modeling of the Bisphenols BPA, BPS, BPF, and BPAF with New Experimental Metabolic Parameters: Comparing the Pharmacokinetic Behavior of BPA with Its Substitutes
por: Karrer, Cecile, et al.
Publicado: (2018)

Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling Site
por: Musther, Helen, et al.
Publicado: (2015)

In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition
por: Murata, Yukiko, et al.
Publicado: (2022)

Bioavailability of IgG Administered by the Subcutaneous Route
por: Berger, Melvin, et al.
Publicado: (2013)

Quantitative Proteomics of Hepatic Drug‐Metabolizing Enzymes and Transporters in Patients With Colorectal Cancer Metastasis
por: Vasilogianni, Areti‐Maria, et al.
Publicado: (2022)

Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects
por: Vasilogianni, Areti‐Maria, et al.
Publicado: (2021)

Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
por: Vasilogianni, Areti-Maria, et al.
Publicado: (2023)

Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure.
por: Clewell, Rebecca A, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_bg6bur68l5poanj13v5uf7nbtc